Adverse Drug Reactions and Interactions — MCQs
Identify the correct match, regarding the drug and its adverse effect.
Which of the following medications does not interact with warfarin?
The anticoagulant activity of warfarin can be reduced by all of the following except.
What is the most common gastrointestinal side effect of oral contraceptives?
Which of the following is classified as a Type E adverse reaction?
Which of the following statements represents the most clinically significant aspect of drug metabolism?
Which one of the following is true for competitive antagonism?
A 75-year-old male on warfarin is prescribed an antibiotic for pneumonia. Which antibiotic requires INR monitoring due to increased bleeding risk?
Which of the following combinations can result in severe toxicity due to inhibition of cytochrome P450 enzymes?
A 42-year-old man was seen in the clinic because of pain and redness in his finger. Last week he had injured the finger while working in his garage. On physical examination, there is erythema, swelling, and tenderness of the second digit in the right hand. Flexion and extension of the finger were normal. A clinical diagnosis of cellulitis is made and he is prescribed cephalexin. A few days later he presents to the emergency room complaining of difficulty breathing. He has angioedema due to a drug reaction to the cephalexin. Which of the following physical findings is characteristic of this syndrome?
Adverse Drug Reactions and Interactions Indian Medical PG Practice Questions and MCQs
Question 1: Identify the correct match, regarding the drug and its adverse effect.
- A. Aliskiren - hypokalemia
- B. Hydralazine - heart failure
- C. Atenolol - hemolytic anemia
- D. Verapamil - constipation (Correct Answer)
Explanation: ***Verapamil - Constipation*** - **Verapamil**, a **non-dihydropyridine calcium channel blocker**, frequently causes constipation due to its effect on smooth muscle in the gastrointestinal tract, leading to **decreased intestinal motility**. - This adverse effect is common and often dose-dependent, making it a significant consideration in patient management. *Aliskiren - hypokalemia* - **Aliskiren**, a **direct renin inhibitor**, can cause **hyperkalemia** by reducing angiotensin II levels, which normally stimulate aldosterone secretion. - It does not typically cause hypokalemia; rather, potassium-sparing effects are often observed. *Hydralazine - heart failure* - **Hydralazine** is a **vasodilator** used to treat hypertension and **heart failure** with reduced ejection fraction by reducing afterload. - It does not cause heart failure; instead, it is often prescribed to improve cardiac function in patients with heart failure. *Atenolol - hemolytic anemia* - **Atenolol** is a **beta-blocker** primarily used for hypertension, angina, and arrhythmias. - **Hemolytic anemia** is a rare adverse effect associated with certain drugs, but it is not a known or common side effect of atenolol.
Question 2: Which of the following medications does not interact with warfarin?
- A. Barbiturate
- B. Oral contraceptive
- C. Cephalosporins
- D. Benzodiazepines (Correct Answer)
Explanation: ***Benzodiazepines*** - **Benzodiazepines** are generally considered safe to use with warfarin as they are extensively metabolized in the liver, but they do not typically alter the **cytochrome P450 enzymes** responsible for warfarin metabolism. - They also do not interfere with **vitamin K recycling** or **platelet function**, which are key mechanisms through which other drugs interact with warfarin. *Barbiturate* - **Barbiturates** are **potent inducers of hepatic enzymes**, particularly CYP2C9, which is responsible for metabolizing warfarin. - This enzyme induction leads to **increased warfarin metabolism**, reducing its anticoagulant effect and necessitating higher warfarin doses. *Oral contraceptive* - **Oral contraceptives** can **reduce the anticoagulant effect of warfarin** by inducing clotting factors or inhibiting warfarin metabolism. - This interaction can increase the risk of **thromboembolic events** in patients on warfarin. *Cephalosporins* - Certain **cephalosporins**, especially those with a **methylthiotetrazole (MTT) side chain** (e.g., Cefamandole, Cefoperazone, Moxalactam), can **inhibit vitamin K epoxide reductase**. - This inhibition leads to a **decrease in vitamin K-dependent clotting factors**, thus potentiating the anticoagulant effect of warfarin and increasing bleeding risk.
Question 3: The anticoagulant activity of warfarin can be reduced by all of the following except.
- A. Aspirin (Correct Answer)
- B. Rifampin
- C. Vitamin K
- D. Carbamazepine
Explanation: ***Aspirin*** - **Aspirin** does NOT reduce warfarin's anticoagulant activity; instead, it increases the risk of bleeding through a synergistic effect. - Aspirin inhibits platelet aggregation via **cyclooxygenase-1 (COX-1)** inhibition, preventing thromboxane A2 formation, which is a different mechanism from warfarin's inhibition of vitamin K-dependent clotting factors. - When combined with warfarin, aspirin **potentiates** the overall antithrombotic effect and increases bleeding risk. *Carbamazepine* - **Carbamazepine** is a potent inducer of hepatic cytochrome P450 enzymes (CYP2C9, CYP3A4). - By increasing warfarin metabolism, it **reduces** warfarin's plasma concentrations and decreases its anticoagulant effect. - Patients on this combination may require higher warfarin doses to maintain therapeutic INR. *Rifampin* - **Rifampin** is one of the most potent inducers of hepatic cytochrome P450 enzymes (CYP2C9, CYP3A4). - It significantly increases warfarin metabolism, leading to **reduced** plasma concentrations and diminished anticoagulant effect. - This interaction often necessitates substantial increases in warfarin dosage. *Vitamin K* - **Vitamin K** is the direct antagonist of warfarin's mechanism of action. - Warfarin inhibits vitamin K epoxide reductase, preventing the regeneration of active vitamin K needed for synthesis of clotting factors II, VII, IX, and X. - Administration of vitamin K **reverses** warfarin's anticoagulant effect by bypassing the inhibited enzyme and restoring clotting factor production.
Question 4: What is the most common gastrointestinal side effect of oral contraceptives?
- A. Decreased appetite
- B. Weight loss
- C. Nausea (Correct Answer)
- D. Constipation
Explanation: ***Nausea*** - **Nausea** is a very common gastrointestinal side effect of oral contraceptives, especially during the initial weeks of use, due to the **estrogen component**. - This side effect often **improves over time** as the body adjusts, or can be managed by taking the pill with food or at bedtime. *Weight loss* - Oral contraceptives are **not typically associated with weight loss**; in fact, some users may experience slight weight gain, although studies show no consistent significant effect. - Changes in weight are more often due to **fluid retention** rather than true fat loss. *Decreased appetite* - **Decreased appetite** is not a common side effect of oral contraceptives; rather, some individuals might experience an increased appetite due to hormonal fluctuations. - The hormonal effects on metabolism and appetite are **varied and not consistently demonstrated** to lead to decreased appetite. *Constipation* - **Constipation** is not a frequent gastrointestinal side effect of oral contraceptives; rather, some users may experience changes in bowel habits, but **diarrhea is more commonly reported** than constipation when GI issues occur. - Hormonal contraceptives primarily affect the gut through **estrogen and progestin**, leading to various effects, but constipation is not a predominant one.
Question 5: Which of the following is classified as a Type E adverse reaction?
- A. Toxicity
- B. Augmented effect
- C. Teratogenesis
- D. Rebound effect due to drug withdrawal (Correct Answer)
Explanation: ***Rebound effect due to drug withdrawal*** - Type E adverse reactions are related to **end-of-treatment effects**, specifically withdrawal phenomena. - The **rebound effect** after drug cessation, such as worsened angina after stopping beta-blockers, is a classic example of a Type E reaction. *Toxicity* - This is a general term for adverse effects from excessive drug doses and is **not a specific type** in the ABCDEF classification. - Dose-dependent toxic effects typically align with **Type A** (augmented) reactions, which are predictable and related to the drug's pharmacology. *Augmented effect* - An **augmented effect** is classified as a Type A adverse drug reaction, meaning it is **dose-dependent**, predictable from the drug's known pharmacology, and common. - Examples include bleeding with anticoagulants or hypotension with antihypertensives. *Teratogenesis* - **Teratogenesis** refers to drug-induced fetal malformations and is categorized as a **Type D** (delayed) adverse drug reaction. - These effects are often severe, occur after prolonged exposure, and are rare.
Question 6: Which of the following statements represents the most clinically significant aspect of drug metabolism?
- A. Most common enzyme involved is CYP 3A4/5 (Correct Answer)
- B. Glucuronidation is a phase II reaction
- C. Reduction is a phase I reaction
- D. Cytochrome P450 is involved in phase I reactions
Explanation: ***Most common enzyme involved is Cyp 3A4/5*** - CYP3A4/5 is the **most abundant and clinically significant** cytochrome P450 enzyme, responsible for metabolizing approximately **50% of all clinically used drugs**. - Its widespread involvement means variations in its activity (due to **genetics, drug interactions, or disease**) have a major impact on drug efficacy and toxicity. *Glucuronidation is a phase II reaction* - While correct that glucuronidation is a **Phase II metabolic reaction**, this statement describes a biochemical classification rather than a clinically significant aspect compared to the involvement of CYP3A4/5. - Phase II reactions generally involve **conjugation** to increase water solubility and facilitate excretion, but they do not collectively account for as many drug interactions as CYP3A4/5 alone. *Reduction is a phase I reaction* - This statement is factually correct as **reduction** is indeed a **Phase I metabolic reaction**. - However, it represents a generic classification of a metabolic pathway and doesn't highlight the specific clinical importance or prevalence of a particular enzyme or reaction in drug metabolism. *Cytochrome P450 is involved in phase I reactions* - This is true; the **cytochrome P450 system** is the primary enzyme system for **Phase I metabolism**, which introduces or exposes polar groups to make drugs more reactive. - While fundamentally important, this statement is too broad; it does not specify the most clinically significant *aspect* or *enzyme* within the P450 system compared to directly identifying CYP3A4/5.
Question 7: Which one of the following is true for competitive antagonism?
- A. Agonist and competitive antagonist bind to the same receptor (Correct Answer)
- B. Agonist cannot displace an antagonist from the receptor
- C. Antagonism cannot be completely reversed by an increased dose of an agonist
- D. Maximum response (Emax) is reduced in the presence of a competitive antagonist
Explanation: ***Agonist and competitive antagonist bind to the same receptor*** - In **competitive antagonism**, both the **agonist** and the **antagonist** compete for the **same binding site** on the receptor. - This competition means that the effect of the antagonist can be **overcome by increasing the concentration of the agonist** (reversible antagonism). - The binding is **reversible** and depends on the **relative concentrations** and affinities of both molecules. *Agonist cannot displace an antagonist from the receptor* - This is **incorrect** for competitive antagonism; a high concentration of the **agonist** can indeed displace the antagonist from the receptor binding site. - This **reversibility** is a defining characteristic of competitive antagonism. *Antagonism cannot be completely reversed by an increased dose of an agonist* - This is **false** for competitive antagonism; a sufficiently high dose of **agonist** can completely overcome the effect of a competitive antagonist. - This describes **non-competitive** or **irreversible antagonism**, not competitive antagonism. *Maximum response (Emax) is reduced in the presence of a competitive antagonist* - This is **incorrect** for competitive antagonism; the **Emax remains unchanged**. - In competitive antagonism, only the **EC50 increases** (curve shifts right), but the maximum response is still achievable with sufficient agonist. - **Reduced Emax** is characteristic of **non-competitive antagonism**.
Question 8: A 75-year-old male on warfarin is prescribed an antibiotic for pneumonia. Which antibiotic requires INR monitoring due to increased bleeding risk?
- A. Ciprofloxacin (Correct Answer)
- B. Amoxicillin
- C. Clindamycin
- D. Azithromycin
Explanation: ***Ciprofloxacin*** - **Ciprofloxacin** and other fluoroquinolones can interact with **warfarin**, though the mechanism is **not well-established** and likely multifactorial (may involve gut flora disruption, protein binding displacement, or metabolic effects). - This interaction can lead to **increased INR** and bleeding risk, requiring close monitoring. - Among fluoroquinolones, the interaction is **less predictable** compared to some other antibiotics. *Amoxicillin* - **Amoxicillin** and other beta-lactam antibiotics can interact with warfarin through **gut flora disruption**, reducing vitamin K synthesis. - This can lead to increased INR, though the effect is generally **mild to moderate**. - Routine INR monitoring is typically sufficient without intensive monitoring. *Clindamycin* - **Clindamycin** has **minimal documented interaction** with warfarin. - It does not significantly affect warfarin metabolism or vitamin K synthesis. - Generally considered a **safer option** for patients on warfarin therapy. *Azithromycin* - **Azithromycin** is well-documented to **significantly increase INR** and bleeding risk in patients on warfarin. - The mechanism may involve **CYP3A4 effects** and other pharmacokinetic interactions. - **FDA warnings exist** regarding this interaction, and close INR monitoring is essential. - Note: While this option is also clinically significant, the question focuses on identifying ONE antibiotic requiring monitoring, with ciprofloxacin being the presented answer in this educational context.
Question 9: Which of the following combinations can result in severe toxicity due to inhibition of cytochrome P450 enzymes?
- A. Amiodarone + Atorvastatin
- B. Carbamazepine + Atorvastatin
- C. Atorvastatin + Itraconazole (Correct Answer)
- D. Phenytoin + Atorvastatin
Explanation: ***Atorvastatin + Itraconazole*** - **Itraconazole** is a potent inhibitor of **CYP3A4**, the primary enzyme responsible for atorvastatin's metabolism. - Co-administration leads to significantly increased **atorvastatin plasma concentrations**, raising the risk of severe side effects like **rhabdomyolysis** and **hepatotoxicity**. *Amiodarone + Atorvastatin* - **Amiodarone** is a moderate **CYP3A4 inhibitor** and can increase atorvastatin levels, but the inhibition is **less potent** than itraconazole. - While this combination does carry a risk and requires dose adjustment, the interaction is **less severe** compared to the potent inhibition seen with itraconazole. - The direct CYP inhibition leading to severe atorvastatin toxicity is less pronounced than with itraconazole. *Carbamazepine + Atorvastatin* - **Carbamazepine** is a potent **CYP3A4 inducer**, meaning it would increase the metabolism of atorvastatin, potentially *decreasing* its efficacy rather than causing toxicity through inhibition. - This interaction would typically lead to subtherapeutic atorvastatin levels, rather than severe toxicity. *Phenytoin + Atorvastatin* - **Phenytoin** is also a potent **CYP3A4 inducer**, similar to carbamazepine. - Concurrent use would likely lead to enhanced metabolism and **reduced efficacy of atorvastatin**, not increased toxicity due to enzyme inhibition.
Question 10: A 42-year-old man was seen in the clinic because of pain and redness in his finger. Last week he had injured the finger while working in his garage. On physical examination, there is erythema, swelling, and tenderness of the second digit in the right hand. Flexion and extension of the finger were normal. A clinical diagnosis of cellulitis is made and he is prescribed cephalexin. A few days later he presents to the emergency room complaining of difficulty breathing. He has angioedema due to a drug reaction to the cephalexin. Which of the following physical findings is characteristic of this syndrome?
- A. Invariably severe itching
- B. Prolonged nature of the edema
- C. Fluid extravasation from subcutaneous and intradermal postcapillary venules
- D. Involvement of lips, tongue, eyelids, genitalia, and dorsum of hands or feet (Correct Answer)
Explanation: ***Involvement of lips, tongue, eyelids, genitalia, and dorsum of hands or feet*** - **Angioedema** is characterized by episodic, localized swelling of the deeper dermal and subcutaneous tissues, often affecting the **lips, tongue, eyelids, genitalia, and dorsum of hands or feet** [1]. - This distribution is due to the **loose connective tissue** in these areas, which allows for significant fluid accumulation. *Invariably severe itching* - While angioedema can sometimes be accompanied by itching, **severe itching (pruritus)** is more characteristic of **urticaria** (hives), which involves the superficial dermis [1]. - In many cases of angioedema, particularly **bradykinin-mediated types**, itching is absent or minimal. *Prolonged nature of the edema* - The edema in **angioedema** typically resolves within **24 to 72 hours**, not weeks or months, differentiating it from other chronic inflammatory conditions. - Its self-limiting nature is a key diagnostic feature, although recurrence is common. *Fluid extravasation from subcutaneous and intradermal postcapillary venules* - **Fluid extravasation** from postcapillary venules occurs in both urticaria and angioedema. However, in angioedema, the fluid extravasation occurs at the level of the **deep dermis and subcutaneous tissue**, leading to deeper swelling. - In **urticaria**, the extravasation is more superficial, affecting the **epidermis and superficial dermis**, resulting in itchy wheals.
Want unlimited practice?
Get full access to all questions, explanations, and performance tracking.
Start For Free